TY - JOUR
T1 - Section 3. Colombian consensus on the diagnosis and treatment of extrapulmonary aspergillosis in adult patients*
AU - Oñate, José M.
AU - Rivas-Pinedo, Pilar
AU - Castañeda-Luquerna, Ximena
AU - Marín-Uribe, Jorge I.
AU - Berrio, Indira
AU - Fernández-Suarez, Hugo
AU - Osorio-Lombana, Juan P.
AU - Cuervo-Maldonado, Sonia I.
AU - Saavedra-Trujillo, Carlos H.
AU - Celis, Adriana Marcela
AU - Álvarez-Moreno, Carlos A.
AU - Gómez-Rincón, Julio C.
AU - Restrepo-Gualteros, Sonia
AU - Camacho-Moreno, Germán
AU - Enciso-Olivera, Leonardo
AU - Patiño-Escobar, Bonell
AU - Guevara, Fredy
AU - Patiño-Niño, Jaime
AU - Montufar, Franco
AU - López-Medina, Eduardo
AU - Fernández-Chico, Dinno
AU - García-Goez, José F.
AU - Pallares, Christian
N1 - Publisher Copyright:
© 2022 Asociacion Colombiana de Infectologia. All rights reserved.
PY - 2022
Y1 - 2022
N2 - The clinical manifestations of Aspergillus spp. associated diseases are variable and depend on the interaction between the inoculating dose (which is not known and probably varies widely), the patient’s ability to resist infection at both local and systemic level, and the virulence of the etiologic agent. The major difficulty in establishing a clinical classification scheme lies in the existence of a broad and continuous spectrum of disease, associated with a complicated diagnosis and clinical management. An IA can present as a localized infection in one organ, or as part of a disseminated infection, which presents itself in a varied spectrum of clinical pictures. However, no clinical trials have been completed to evaluate the different specific therapeutic approaches according to the type of involvement in these patients. The most common clinical forms of invasive aspergillosis (IA) occur in the lung and paranasal sinuses, chronic pulmonary aspergillosis (CPA) can be complicated by spreading to contiguous structures such as the pleural space, pericardium, chest wall and mediastinal structures such as the esophagus and great vessels. It frequently spreads beyond the respiratory tract, and can affect the skin, CNS, eyes, liver, kidneys and other structures.
AB - The clinical manifestations of Aspergillus spp. associated diseases are variable and depend on the interaction between the inoculating dose (which is not known and probably varies widely), the patient’s ability to resist infection at both local and systemic level, and the virulence of the etiologic agent. The major difficulty in establishing a clinical classification scheme lies in the existence of a broad and continuous spectrum of disease, associated with a complicated diagnosis and clinical management. An IA can present as a localized infection in one organ, or as part of a disseminated infection, which presents itself in a varied spectrum of clinical pictures. However, no clinical trials have been completed to evaluate the different specific therapeutic approaches according to the type of involvement in these patients. The most common clinical forms of invasive aspergillosis (IA) occur in the lung and paranasal sinuses, chronic pulmonary aspergillosis (CPA) can be complicated by spreading to contiguous structures such as the pleural space, pericardium, chest wall and mediastinal structures such as the esophagus and great vessels. It frequently spreads beyond the respiratory tract, and can affect the skin, CNS, eyes, liver, kidneys and other structures.
KW - amphotericin B
KW - anidulafungin
KW - aspergillosis
KW - Aspergillus
KW - Aspergillus diagnosis
KW - caspofungin
KW - central nervous system
KW - endocarditis
KW - endophthalmitis
KW - extra pulmonary aspergillosis
KW - guidelines
KW - invasive aspergillosis
KW - isavuconazole
KW - micafungin
KW - osteomyelitis
KW - posaconazole
KW - sinusitis
KW - voriconazole
UR - http://www.scopus.com/inward/record.url?scp=85152702368&partnerID=8YFLogxK
U2 - 10.22354/24223794.1065
DO - 10.22354/24223794.1065
M3 - Artículo
AN - SCOPUS:85152702368
SN - 0123-9392
VL - 26
SP - 338
EP - 357
JO - Infectio
JF - Infectio
IS - 3
ER -